Topic Paragraphs
Donate COVID-19 Plasma
If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma.
Featured Topics
New Era of Smarter Food Safety
A new approach to food safety that recognizes and builds on the progress made in the past but looks towards what processes and tools will be needed for the future.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Aug 10
Progressive Produce Voluntarily Recalls Red and Yellow Onions Because of Possible Health Risk
Food & Beverages
Aug 09
Wegmans Food Markets, Inc. Announces Recall of Select Valencia Oranges, Lemons, and Various Products Containing Fresh Lemon Because of Possible Health Risk
Food & Beverages
Aug 09
Soluciones Cosméticas Issues Voluntary Nationwide Recall of Bersih Hand Sanitizer Gel Due to The Potential Presence of Undeclared Methanol (Wood Alcohol): Updated August 7, 2020
Drugs
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
An Exciting New Chapter in OTC Drug History: OTC Monograph Reform in the CARES Act
The CARES Act includes OTC monograph reform provisions granting the FDA new authorities to modernize OTC monograph drug development and review.
Investing in Advanced Manufacturing to Support Public Health Preparedness
For the past several years, the U.S. Food and Drug Administration has sought to encourage and facilitate the adoption of Advanced Manufacturing.
Potential Risks of Treatment with Unapproved Regenerative Medicine Products
FDA is providing resources to help consumers understand the risks associated with unapproved stem cell, exosome, and products marketed as regenerative medicine.